Oncology Research Program

The Institute's oncology program centers on cell therapy through its induced pluripotent stem cell (iPSC).

The Institute's research focuses on allogeneic (off-the shelf) iPSC program in which the iPSC are immune-tolerant and will not be rejected when administered to unrelated recipients.  The Institute's cell therapy is based on its first-in-class virus-free and oncogene-free iPSC program coupled with its immune-tolerant adult stem cell platform.  This research program will focus on the following treatments:

  1. Universal bone marrow hematopoietic stem cells.

  2. Universal CAR-T/NKC therapy for hematological cancers.

  3. Universal CAR-T/NKC therapy for solid organ cancers.

© 2019 John Paul II Medical Research Institute.